Search Results - "Vickerman, Peter"

Overdose prevention centres as spaces of safety, trust and inclusion: A causal pathway based on a realist review.

Authors: Stevens, Alex Keemink, Jolie R. Shirley‐Beavan, Sam et al.

Source: Drug & Alcohol Review. Sep2024, Vol. 43 Issue 6, p1573-1591.

Cost‐effectiveness of integrated treatment for hepatitis C virus (HCV) among people who inject drugs in Norway: An economic evaluation of the INTRO‐HCV trial.

Authors: Lim, Aaron Guanliang Aas, Christer Frode Çağlar, Ege Su et al.

Source: Addiction. Dec2023, Vol. 118 Issue 12, p2424-2439.

The Golden Halo of Defaults in Simple Choices.

Authors: Sullivan, Nicolette J. Breslav, Alexander Doré, Samyukta S. et al.

Source: Journal of Marketing Research (JMR). Apr2025, Vol. 62 Issue 2, p386-404. 19p.

Association between opioid agonist therapy use and HIV testing uptake among people who have recently injected drugs: a systematic review and meta‐analysis.

Authors: Ferraro, Claire F. Stewart, Daniel E. Grebely, Jason et al.

Source: Addiction. Jul2021, Vol. 116 Issue 7, p1664-1676.

Modeling the population‐level impact of opioid agonist treatment on mortality among people accessing treatment between 2001 and 2020 in New South Wales, Australia.

Authors: Chaillon, Antoine Bharat, Chrianna Stone, Jack et al.

Source: Addiction. May2022, Vol. 117 Issue 5, p1338-1352.

Prevalence, trends, and distribution of hepatitis C virus among the general population in sub‐Saharan Africa: A systematic review and meta‐analysis.

Authors: Kassa, Getahun Molla Walker, Josephine G. Alamneh, Tesfa Sewunet et al.

Source: Liver International. Dec2024, Vol. 44 Issue 12, p3238-3249. 12p.

Universal testing for hepatitis B and hepatitis C in the emergency department: a cost-effectiveness and budget impact analysis of two urban hospitals in the United Kingdom.

Authors: Williams, Jack Vickerman, Peter Smout, Elizabeth et al.

Source: Cost Effectiveness & Resource Allocation. 11/14/2022, Vol. 20 Issue 1, p1-12. 12p.

Seroprevalence of Hepatitis C in Ethiopia: First National Study Based on the 2016 Ethiopian Demographic and Health Survey.

Authors: Kassa, Getahun Molla Weldemariam, Atsbeha Gebreegziabxier Abrahim, Saro Abdella et al.

Source: Journal of Viral Hepatitis. Apr2025, Vol. 32 Issue 4, p1-11. 11p.

Cost‐effectiveness of scaling‐up HCV prevention and treatment in the United States for people who inject drugs.

Authors: Barbosa, Carolina Fraser, Hannah Hoerger, Thomas J. et al.

Source: Addiction. Dec2019, Vol. 114 Issue 12, p2267-2278.

Hepatitis C treatment outcomes among people who inject drugs accessing harm reduction settings in Kenya.

Authors: Akiyama, Matthew J. Riback, Lindsey R. Nyakowa, Mercy et al.

Source: Journal of Viral Hepatitis. Aug2022, Vol. 29 Issue 8, p691-694. 4p.

Cost‐effectiveness of the HepCATT intervention in specialist drug clinics to improve case‐finding and engagement with HCV treatment for people who inject drugs in England.

Authors: Ward, Zoe Reynolds, Rosie Campbell, Linda et al.

Source: Addiction. Aug2020, Vol. 115 Issue 8, p1509-1521.

Presenting a conceptual framework for an HIV prevention and care continuum and assessing the feasibility of empirical measurement in Estonia: A case study.

Authors: Uusküla, Anneli Vickerman, Peter Raag, Mait et al.

Source: PLoS ONE. 10/9/2020, Vol. 15 Issue 10, p1-15. 15p.

Evaluating the cost‐effectiveness of existing needle and syringe programmes in preventing hepatitis C transmission in people who inject drugs.

Authors: Sweeney, Sedona Ward, Zoe Platt, Lucy et al.

Source: Addiction. Mar2019, Vol. 114 Issue 3, p560-570.

Incidence of hepatitis C virus infection in the prison setting: The SToP‐C study.

Authors: Hajarizadeh, Behzad Carson, Joanne M. Byrne, Marianne et al.

Source: Journal of Viral Hepatitis. Jan2024, Vol. 31 Issue 1, p21-34. 14p.

Response to Commentary on Hancock et al. (2020): Low dead space syringes are just one component of an integrated package of care needed to tackle HCV and social exclusion among people who inject drugs.

Authors: Kesten, Joanna Ward, Zoe Hancock, Elizabeth et al.

Source: Addiction. Dec2020, Vol. 115 Issue 12, p2407-2408. 2p.

Subjects: Intravenous drug abuse, Hepatitis C transmission, Syringes

Detachable low dead space syringes for the prevention of hepatitis C among people who inject drugs in Bristol, UK: an economic evaluation.

Authors: Hancock, Elizabeth Ward, Zoe Ayres, Rachel et al.

Source: Addiction. Apr2020, Vol. 115 Issue 4, p702-713.

Overlapping substance using high-risk groups and infectious diseases: how dynamic modelling can evaluate risk and target HIV prevention.

Authors: Martin, Natasha K. Vickerman, Peter Hickman, Matthew et al.

Source: Addiction. Sep2016, Vol. 111 Issue 9, p1512-1515. 4p. 1 Diagram, 1 Graph.

Subjects: Dynamic models, Epidemics, HIV infection risk factors, HIV infections, Therapeutics, Treatment effectiveness, Hepatitis C prevention, Hepatitis C risk factors, HIV prevention, HIV infection epidemiology, Biological models, Risk-taking behavior, Human sexuality, Substance abuse, Disease prevalence, Mixed infections

Geographic Terms: Mexico

RESPONSE TO THE COMMENTARIES.

Authors: MACLEOD, JOHN HICKMAN, MATTHEW VICKERMAN, PETER et al.

Source: Addiction. Apr2007, Vol. 102 Issue 4, p516-518. 3p.

Subjects: Editorials, Marijuana abuse, Drug abuse, Schizophrenia, Psychoses

Geographic Terms: England, Wales

HepFREEPak: protocol for a multi-centre, prospective observational study examining efficacy and impact of current therapies for the treatment of hepatitis C in Pakistan and reporting resistance to antiviral drugs: study protocol.

Authors: Arif, Ambreen Hasnain, Aliya Chaudhry, Auj et al.

Source: BMC Public Health. 12/18/2023, Vol. 23 Issue 1, p1-9. 9p.

Referees.

Source: Addiction. May2007, Vol. 102 Issue 5, p836-840. 5p.

Subjects: Publishing, Editors, Authors, Author-publisher relations, Aalto, Mauri